10-Q: Actinium Q3: Pipeline Progress Amidst Financial Headwinds

Actinium Pharmaceuticals reports reduced net loss in Q3 2025, driven by cost cuts, but faces significant cash burn, Iomab-B regulatory setbacks, and ongoing legal challenges.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $5.1 million from $11.6 million in the prior-year period.
• Net loss for the nine months ended September 30, 2025, decreased to $27.9 million from $31.6 million in the prior-year period.
• Cash and cash equivalents decreased to $53.4 million as of September 30, 2025, from $72.9 million at December 31, 2024.
• Research and development expenses decreased by $5.6 million for the three months and $8.4 million for the nine months ended September 30, 2025, primarily due to reduced CRO services, preclinical R&D, and lower headcount.
• General and administrative expenses decreased by $1.3 million for the three months ended September 30, 2025, but increased by $3.7 million for the nine months, largely due to a $3.9 million increase in non-cash stock-based compensation from option cancellations.
• The company conducted a workforce optimization in Q2 2025, reducing headcount by approximately 14% and implementing a strategic pipeline prioritization.
• Preclinical data for ATNM-400, the lead program, showed superior efficacy and improved survival in prostate cancer models compared to Pluvicto and enzalutamide, and synergistic activity in NSCLC models.
• The FDA determined that the Iomab-B Phase 3 SIERRA trial alone is not adequate for a Biologics License Application (BLA) filing, requiring additional randomized head-to-head and dose optimization trials.
• A securities class action and two derivative shareholder complaints were filed in March and May 2025, respectively, alleging misrepresentations regarding the Iomab-B Sierra Trial.
• The recent U.S. federal government shutdown (October 1 to November 12, 2025) is expected to delay current and planned trials under the Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant cash burn, a major regulatory setback for Iomab-B requiring new trials, and ongoing legal challenges. While preclinical data for ATNM-400 is promising and R&D expenses were reduced, these positives are overshadowed by the financial and regulatory hurdles, and the early stage of the most promising pipeline assets.

Positives

• Net loss significantly decreased for both the three-month ($5.1 million vs. $11.6 million) and nine-month ($27.9 million vs. $31.6 million) periods ended September 30, 2025, compared to 2024.
• Research and development expenses decreased by $5.6 million for the three months and $8.4 million for the nine months ended September 30, 2025, reflecting cost management and strategic pipeline prioritization.
• ATNM-400, the lead program, demonstrated potent and durable efficacy in preclinical prostate cancer models, outperforming Pluvicto and enzalutamide, and showed synergistic activity in NSCLC models.
• New preclinical data for ATNM-400 in breast cancer models will be presented, expanding its pan-tumor potential.
• The Actimab-A program is advancing through a CRADA with the NCI, which covers clinical trial execution and development expenses, offering a cost-efficient development pathway.
• Initial proof of concept clinical data for Iomab-ACT in commercial CAR-T therapy and sickle cell disease trials is expected in the first half of 2026.
• The company possesses proprietary Ac-225 cyclotron manufacturing technology with 5 U.S. and 33 international patents, offering potential for lower-cost, scalable production.
• Existing resources are expected to fund planned operations for more than 12 months from the filing date of November 14, 2025.

Negatives

• Cash and cash equivalents decreased by $19.5 million, from $72.9 million at December 31, 2024, to $53.4 million at September 30, 2025, indicating significant cash burn.
• Accumulated deficit increased to $403.8 million as of September 30, 2025, from $375.8 million at December 31, 2024.
• Total stockholders' equity significantly decreased to $13.8 million as of September 30, 2025, from $32.8 million at December 31, 2024.
• The FDA determined that the Iomab-B Phase 3 SIERRA trial alone is not adequate to support a BLA filing, requiring additional randomized head-to-head and dose optimization trials, which delays potential commercialization in the U.S.
• General and administrative expenses increased by $3.7 million for the nine months ended September 30, 2025, primarily due to $3.9 million in non-cash stock-based compensation from option cancellations.
• The company is actively seeking a strategic partner for Iomab-B in the U.S. to execute the newly required Phase 2/3 clinical trial, indicating a lack of internal resources or willingness to fund this program alone.
• Novartis Pharmaceuticals Corporation issued a letter objecting to Actinium's promotional claims for ATNM-400, citing pre-approval promotion and misleading comparisons to Pluvicto, which could lead to regulatory scrutiny.

Risks

• The company is a clinical-stage company with no revenue from commercial sales to date and has incurred net losses since inception, anticipating continued losses.
• Failure to obtain additional financing will prevent continuation or completion of product development or commercialization, potentially leading to loss of investment.
• High dependence on the clinical, regulatory, and commercial success of ATNM-400, Actimab-A, Iomab-ACT, and other pipeline candidates, which may never achieve approval.
• Business strategy modifications, such as divestitures, spin-offs, mergers, or acquisitions, if unsuccessful, could materially adversely affect the business.
• Clinical trials may fail to demonstrate adequate efficacy and safety, preventing or delaying regulatory approval and commercialization.
• Preliminary, interim, and top-line data from clinical trials may change as more data become available and are subject to audit and verification, potentially resulting in material changes in final data.
• Healthcare legislative reform measures, including those aimed at reducing pharmaceutical product prices (e.g., Inflation Reduction Act), could materially adversely affect future revenue and results of operations.
• Reliance on third parties to conduct certain aspects of clinical trials poses risks if they do not successfully carry out duties, meet deadlines, or comply with regulatory requirements.
• Dependence on single third-party manufacturers for preclinical and clinical trial drug supplies, with any disruption adversely affecting business operations.
• Product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• Disruptions at the FDA and other government agencies (e.g., government shutdowns, funding shortages) could hinder timely reviews and approvals, negatively impacting the business.
• Uncertainty in patent position and complex legal/factual questions, with patents potentially challenged, invalidated, or circumvented.
• High dependence on key personnel and intense competition for talent in the biotechnology industry.
• Exposure to cybersecurity risks, including theft of intellectual property or disruption of operations.
• Potential for claims that employees have wrongfully used or disclosed confidential information of third parties.
• Compliance with reporting requirements of federal securities laws can be expensive.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.

Future Outlook

The company expects its existing resources to be sufficient to fund planned operations for more than 12 months from the filing date. It plans to continue advancing its clinical and preclinical pipeline, including initiating new trials under the NCI CRADA and seeking strategic partners for Iomab-B in the U.S. and other non-solid tumor indications. Initial proof of concept clinical data for Iomab-ACT is anticipated in the first half of 2026. The company also intends to commence the build-out of an in-house manufacturing facility.

Management Comments

• We are a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve outcomes for patients with advanced cancers.
• We are focused on developing highly innovative, first-in-class product candidates.
• To support our objective of achieving industry leading, cost-effective product development to maximize value creation from our innovative pipeline, we are working to expand the scope of our capabilities to include radioisotope production of Ac-225 via collaborations for our Ac-225 technology and in-house manufacturing of pipeline candidates to support clinical trials.
• We believe ATNM-400 has the potential to address critical gaps across multiple treatment settings in each of these targeted indications and can therefore address large patient populations.
• We are actively seeking a strategic partner for Iomab-B, our CD45 targeted conditioning agent for bone marrow transplant (BMT) in the U.S. and we may seek to partner, divest, spin-out, or out-license Iomab-B, Actimab-A, and Iomab-ACT individually or collectively for all non-solid tumor indications.
• We believe, in the aggregate, the clinical data from these hematology and cellular therapy focused programs is supportive of a partnering approach, which if successful, may yield greater value as the Company focuses on its solid tumor development efforts utilizing existing resources.
• We do not agree with any of the claims made in the Novartis Letter and do not believe Novartis has requisite legal authority or basis to challenge Actinium. Therefore, we have not responded to Novartis but reserve all rights.
• We believe patients with mCRPC have high unmet needs that are not addressed by current therapies including Pluvicto and intend to continue to develop ATNM-400 with the goal of addressing these patient needs.

Industry Context

The biopharmaceutical industry, particularly in targeted radiotherapies, is highly competitive and characterized by rapid technological change. Actinium is positioning itself in the growing field of alpha-emitter radiotherapies, which is seeing increased adoption by large biopharmaceutical companies. The company's focus on non-PSMA targets for prostate cancer and novel combinations for NSCLC and AML aims to address significant unmet needs where existing therapies face resistance or limited efficacy. Regulatory changes, such as the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), are impacting drug pricing and healthcare program funding, potentially affecting market protections and reimbursement for new drugs, though Actinium believes its biologic-based orphan drugs may have some exclusions.

Comparison to Industry Standards

• ATNM-400 demonstrated superior efficacy and improved overall survival in preclinical prostate cancer models compared to 177Lu-PSMA-617 (active agent in Pluvicto, Novartis) and enzalutamide (active agent in Xtandi, Astellas/Pfizer).
• In NSCLC models, ATNM-400 showed superior anti-tumor activity compared to currently approved EGFR mutant therapies including osimertinib (TAGRISSO, AstraZeneca), Dato-DXd (DATROWAY, AstraZeneca/Daiichi Sankyo), and amivantamab (RYBREVANT, Johnson & Johnson).
• ATNM-400 demonstrated synergistic activity with osimertinib, achieving complete tumor regression in 100% of tumor-bearing animals, which compares favorably to the 12.3-month improvement in PFS seen with osimertinib combined with external beam radiotherapy (EBRT) over osimertinib monotherapy.
• Actimab-A's potential to deplete MDSCs in combination with PD-1 inhibitors (like KEYTRUDA, Merck, or OPDIVO, Bristol Myers Squibb) aims to address the limitations of current immunotherapies where not all patients have robust or durable responses.
• The 24-month median OS reported in eligible r/r AML patients proceeding to BMT with Actimab-A + CLAG-M compares highly favorably to the <2 to 4-month OS reported in r/r AML patients with high-risk features like TP53 mutations or prior venetoclax therapy.

Management Changes

Legal Proceedings

• A putative class action complaint (Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553) was filed on March 27, 2025, in the U.S. District Court for the Southern District of New York, alleging material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial. The class period is October 31, 2022, to August 2, 2024. Defendants moved to dismiss on October 24, 2025.
• Two derivative shareholder complaints (Georges Complaint and Robinson Complaint) were filed on May 5, 2025, and May 13, 2025, respectively, alleging derivative liability for the same allegations as the Securities Complaint. These were consolidated into the Derivative Action on June 24, 2025, and stayed on July 30, 2025, pending resolution of the motion to dismiss the Securities Complaint.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises, stock price volatility due to regulatory setbacks and legal proceedings, and uncertainty regarding the commercialization of pipeline assets.
• Patients may benefit from the development of new targeted radiotherapies for advanced cancers, but also face delays in access to Iomab-B due to regulatory requirements and potential delays in NCI CRADA trials due to government shutdowns.
• Employees experienced a workforce reduction of approximately 14% in Q2 2025 due to strategic pipeline prioritization, impacting job security and morale.
• Partners (e.g., Immedica, NCI) may experience delays in collaborative projects due to regulatory hurdles or government shutdowns, potentially affecting their investment and timelines.
• Creditors may face increased risk due to the company's ongoing net losses and significant cash burn, although liquidity is projected for over 12 months.

Next Steps

• Advance ATNM-400 into clinical trials.
• Present new preclinical data for ATNM-400 in breast cancer at the San Antonio Breast Cancer Symposium on December 11, 2025.
• Yield initial proof of concept clinical data for Iomab-ACT commercial CAR-T therapy and SCD trials in the first half of 2026.
• Complete the Phase 2 portion of the Actimab-A + CLAG-M trial to optimize the Actimab-A dose in combination with CLAG-M.
• Meet with the FDA after Phase 2 results to determine the optimized Actimab-A dose and obtain feedback on the Phase 3 protocol.
• Initiate new clinical trials under the NCI CRADA, including the frontline AML triplet Phase 1b combination trial.
• Actively seek a strategic partner for Iomab-B in the U.S. to execute the newly required Phase 2/3 clinical trial.
• Commence the build-out of an in-house manufacturing facility to supply final drug product for current and planned clinical trials.
• Continue to explore potential clinical trials for Actimab-A under the CRADA with NCI, investigator-initiated trials, or company sponsorship.
• Lead plaintiffs' opposition to the motion to dismiss the amended Securities Complaint is due in late December 2025.

Key Dates

Recommendation

While Actinium Pharmaceuticals shows promising preclinical data for its lead candidate ATNM-400 and has reduced its net loss through cost management, the significant regulatory setback for Iomab-B, requiring new trials, introduces substantial uncertainty and delays to a key pipeline asset. The company's cash position has deteriorated, and it faces ongoing legal challenges and potential delays from government shutdowns. The long-term potential of its alpha-emitter platform is notable, but the near-term risks and capital requirements warrant a cautious 'hold' stance. Investors should monitor progress on ATNM-400's clinical advancement, Iomab-B's partnering efforts, and the resolution of legal proceedings.

Keywords

Actinium Pharmaceuticals, ATNM, Radiotherapies, Oncology, Cancer treatment, Clinical trials, ATNM-400, Actimab-A, Iomab-ACT, Iomab-B, Alpha-emitter, Ac-225, Prostate cancer, NSCLC, Breast cancer, AML, MDS, Cellular therapy, Gene therapy, FDA approval, SEC filing, Biopharmaceutical, Drug development, Corporate governance, Risk factors, Financial results